Last reviewed · How we verify
Conventional Asthma Therapy
Conventional Asthma Therapy is a Combination therapy (inhaled corticosteroid + short-acting beta-2 agonist) Small molecule drug developed by AstraZeneca. It is currently in Phase 3 development for Persistent asthma (mild to moderate), Acute asthma exacerbations.
Conventional asthma therapy typically combines inhaled corticosteroids to reduce airway inflammation with short-acting beta-2 agonists for acute bronchospasm relief.
Conventional asthma therapy typically combines inhaled corticosteroids to reduce airway inflammation with short-acting beta-2 agonists for acute bronchospasm relief. Used for Persistent asthma (mild to moderate), Acute asthma exacerbations.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
AstraZeneca is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Conventional Asthma Therapy |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Combination therapy (inhaled corticosteroid + short-acting beta-2 agonist) |
| Target | Glucocorticoid receptor; beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Inhaled corticosteroids suppress inflammatory pathways in the airways, reducing mucus production and airway hyperresponsiveness. Short-acting beta-2 agonists activate beta-2 adrenergic receptors on airway smooth muscle, causing rapid bronchodilation. Together, these agents address both the chronic inflammatory component and acute symptoms of asthma.
Approved indications
- Persistent asthma (mild to moderate)
- Acute asthma exacerbations
Common side effects
- Tremor
- Tachycardia
- Oral candidiasis
- Hoarseness
- Headache
- Nervousness/anxiety
Key clinical trials
- High Flow Nasal Cannula Rates in Pediatric Asthma (NA)
- Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment (PHASE3)
- Efficacy of the Sit to Stand Test in the Decision to Hospitalize a Patient Consulting the Emergency Dept for COVID 19 (NA)
- Digital Prevention of Asthma (NA)
- Scalene Hold Relax Technique With Conventional Physical Therapy in Asthma (NA)
- Animated Video and Booklet Education for Improving Asthma Control and Medication Compliance in Children (NA)
- ICS+LABA Vs. ICS+LABA+Omalizumab: Impact on Asthma Control and Gene Expression (PHASE4)
- Peginterferon α-2b Injection for the Treatment of Pediatric RSV Bronchiolitis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Conventional Asthma Therapy CI brief — competitive landscape report
- Conventional Asthma Therapy updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Conventional Asthma Therapy
What is Conventional Asthma Therapy?
How does Conventional Asthma Therapy work?
What is Conventional Asthma Therapy used for?
Who makes Conventional Asthma Therapy?
What drug class is Conventional Asthma Therapy in?
What development phase is Conventional Asthma Therapy in?
What are the side effects of Conventional Asthma Therapy?
What does Conventional Asthma Therapy target?
Related
- Drug class: All Combination therapy (inhaled corticosteroid + short-acting beta-2 agonist) drugs
- Target: All drugs targeting Glucocorticoid receptor; beta-2 adrenergic receptor
- Manufacturer: AstraZeneca — full pipeline
- Therapeutic area: All drugs in Respiratory/Pulmonology
- Indication: Drugs for Persistent asthma (mild to moderate)
- Indication: Drugs for Acute asthma exacerbations
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing